Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326312 · ClinicalTrials.gov registry record · Phase 2
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
A Phase 2 study, sponsored by GTx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT01326312: Clinical Trial Phase 2 study, sponsored by GTx.
NCT01326312 is a Phase 2 study that was terminated before completion, run by GTx. The registered enrollment target is 159 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01326312, a Phase 2 study, was terminated before completion, sponsored by GTx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer.
Interventions
- DRUG Lupron Depot
- DRUG GTx-758 1000mg
- DRUG GTx-758 2000mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Why NCT01326312 stopped before completion
NCT01326312 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 3 interventions - of which Lupron Depot is the first listed.
NCT01326312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01326312 about?
NCT01326312 is a clinical study titled "Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer". The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer.
What is the current status of trial NCT01326312?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2011-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01326312?
The interventions under investigation include: Lupron Depot (DRUG), GTx-758 1000mg (DRUG), GTx-758 2000mg (DRUG).
Who is sponsoring clinical trial NCT01326312?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01326312's enrollment target sits among peer trials
159 442nd of 2000 higher than 1,558 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia